I don’t take any ARBs (for now), but I looked at them as I think way more people could take anti-hypertensive, but the practice varies a lot between countries and doctors due to different national guidelines and the lack of a user-friendly continuous blood pressure monitor. There’s also no equivalent of Hb A1c for blood pressure that would give you the average over the past 3 months with a simple blood test.
Regarding local guidelines: “Americans are advised to start antihypertensive treatment at the levels of 130/80 mmHg, while Europeans at the level of 140/90 mmHg” (American, European and international hypertension guidelines: Time to shake hands? 2021)
Regarding measurements, here are the differences between values taken at the doctor (“Clinic”), by yourself at home, or with a 24h BP monitor: Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations
It’s terrible because “For every 20mmHg increase in systolic blood pressure above normal your risk of dying from a heart attack or stroke doubles.” ( https://twitter.com/Paddy_Barrett/status/1579019655783813120 )
If your doctor doesn’t prescribe a 24-hour BP check and/or if you live in Europe, you might not get the treatment you deserve.
Then, among anti-hypertensive, I would not take beta-blockers (those ending in “-olol”) as they’re consistently linked to a higher rate of Parkinson’s disease, study after study: Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: from multiple real-world evidence. There are so many alternative anti-hypertensives: why take the risk? (especially if you have a family history of Parkinson’s or other neurological diseases)
In particular, according to this paper, “antihypertensive medications that stimulate vs inhibit type 2 and 4 angiotensin II receptors may result in a lower risk of incident dementia” (Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries).
Among them, ARBs (“sartans”) seem especially good. This paper (see Table 2) gives a summary of their potential: The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?
It might be better to prefer ARBs that cross the blood-brain barrier (source):
Telmisartan is also unique in its ability to reduce fasting plasma glucose and increase adiponectin and insulin sensitivity (in addition to its anti-hypertensive properties):
No wonder telmisartan is being tested in the ITP!
(The newer azilsartan seems to have insulin-sensitizing effects as well)